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Abstract
Epidemiological studies have found an increased risk of Parkinson’s disease (PD) with
environmental  factors  such  as  exposure  to  substances  derived  from  industrial
processes, use of agrochemicals, or living in a rural environment. The hypothesis that
certain  environmental  toxins  could  be  the  source  of  the  EP  is  supported  by  the
discovery that chemicals such as herbicides paraquat, diquat, and the fungicide maneb
are selectively toxic in nigrostriatal dopaminergic neurons. Also, one of the insecticides
produced by plants, such as rotenone, and by-product of the synthesis of synthetic
heroin  MPTP  (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)  can  be  reproduced  in
animal models where neurochemicals, histopathological, and clinical characteristic of
PD can  be  found.  Interestingly,  there  are  similarities  in  the  chemical  structure  of
paraquat and MPTP. Recent evidence exhibited that inflammation and oxidative stress
play an essential role in the development of PD. So, in our laboratory we found that
in an animal model melatonin decreases the products of lipid oxidation, nitric oxide
metabolites, and the activity of cyclooxygenase 2, which are induced by an intraperi-
toneal injection of MPTP. This suggests that the neuroprotective effects of melatonin
are partially attributed to its antioxidant scavenging and anti-inflammatory action.
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1. Introduction
Parkinson’s  disease  (PD)  is  a  neurodegenerative  disorder  characterized  by  tremor  and
disruptions to voluntary movement. The main neuropathology in PD involves the death of
dopaminergic  cells  in  the  pars  compacta  of  the  substantia  nigra  with  intracytoplasmic
inclusions  (Lewy bodies)  in  the  remaining  intact  nigral  neurons  [1].  Neural  loss  in  the
substantia nigra increases with age in PD, consistent with a worsening prognosis and increased
symptom severity in older patients. The substantia nigra is an anatomical region of the brain
implicated in dopamine synthesis and voluntary motor control and is a part of the basal
ganglia. Neural circuits in the basal ganglia, particularly the nigrostriatal pathway, appear to
be crucial to the successful execution of both innate and learned motor behaviors [2].
PD primarily affects people of ages 50 and older, and the prevalence and risk of developing
sporadic PD increases substantially with age and has an incidence rate of 18 per 100,000 per
year [3]. As the disease progresses, significant motor disability is seen in PD patients even when
treated with symptomatic medications. Symptoms like dysphagia, sialorrhoea, microphagia,
and dystonia are also well-known. Nonmotor symptoms include cognitive impairment [4],
neuropsychiatric symptoms (depression, psychosis, anxiety, and fatigue), sleep dysfunction
(rapid eye movement sleep behavior disorder, sleep attacks, daytime sleepiness, advanced
sleep phase syndrome, and early morning awakenings) [5], autonomic disturbances (consti-
pation, nausea, orthostatic hypotension, and urogenital problems), and sensory disturbances
(restless legs syndrome, visual changes, and decreased olfaction) [6]. Interestingly, increased
mortality risk has been linked with both motor and nonmotor features in newly diagnosed PD
patients, especially with features like postural instability, hallucinations, and cognitive
impairment [7].
No definitive diagnostic test such as magnetic resonance imaging or computed topography
scans or genetic tests can confirm PD. Its diagnosis is typically based on the presence of a
combination of key motor features, such as associated and exclusionary symptoms, and
response to levodopa [8].
The molecular mechanisms underlying the loss of these neurons still remain elusive. Different
modes of cell death, apoptotic, necrotic, and autophagic, have been described to contribute to
the neuronal loss occurring in PD [9]. Oxidative stress plays an important role in dopaminergic
neurotoxicity. Mitochondrial complex I deficiencies of the respiratory chain account for the
neuronal degeneration in PD. Neurotoxins and other environmental factors, such as pesticides,
insecticides, dopamine metabolites, heavy metals, microbial toxins, and genetic mutations, in
PD-associated proteins contribute to mitochondrial dysfunction [10, 11]. A byproduct of an
illicit narcotic drug, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as well as its
metabolite MPP+, has been shown to cause the same signs and symptoms as PD. In fact,
inhibitors of mitochondrial complex 1 (MPTP, rotenone, and paraquat) are able to reproduce
parkinsonism with selective dopaminergic neuronal loss in mice and primate models [12].
Furthermore, a chronic infusion of either rotenone [13] or MPTP [14] in rodents induces the
formation of α-synuclein positive aggregates. These data support the suggestion that sporadic
PD may be caused by a combination of genetic predisposition and environmental toxins, which
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act via inhibition of the mitochondrial complex I to produce selective dopaminergic cell loss.
Human epidemiological studies have implicated a higher incidence of PD in residents of rural
environments with exposure to herbicides and pesticides [15].
2. Oxidative stress
The body is constantly exposed to the influence and attack of free radicals, which have been
associated with various disorders of the nervous system such as Parkinson disease, the motor
neuron disease, and other disorders of the central nervous system (CNS). A free radical is
considered any molecule containing one or more unpaired electrons. It is produced by
biochemical redox reactions occurring as a result of normal cellular metabolism (biochemical
reactions with oxygen or produced as a result of oxidative stress), as well as by phagocytes in
inflammatory reactions controlled in response to exposure to different environmental factors,
including ionizing radiation, ultraviolet rays, smoking, air pollution, gamma radiation,
hyperoxia, excessive exercise, ischemia, and toxic compounds such as cancer drugs, some
anesthetics, and painkillers [16].
The main free radicals are superoxide anion (O2•–), hydroxyl (OH•), nitric oxide (NO•), and
peroxyl (ROO•) [17]. Some of them are considered highly reactive molecules that can cause
cell damage and even death. Usually, the most damaged cellular components are unsaturated
fatty acids in cell membranes and proteins such as enzymes conveying ions across membranes.
It is estimated that mitochondria are the main source of oxygen radicals (Figure 1) [18] in which
anion superoxide (O2•) is generated during electron transport. Superoxide dismutase (SOD)
converts O2•– to hydrogen peroxide (H2O2) by the Fenton reaction; the latter in the presence
of Fe2+ produces hydroxyl radical (OH•) by reacting Fe2+ and Cu+. Then, the Fenton reaction
is expressed as
O2•– + Fe3+ ____________ Fe2++O2
Fe2+ + H2O2 ____________ Fe3+ + OH– + OH•
O2• + H2O2 ____________ OH– + OH• + O2
According to Burdon and Mattson 1995 and 1998, the O2•– may also interact with nitric oxide
(NO•) to form peroxynitrite (ONOO–). Of all free radicals, OH– is the most damaging free
radical, since its presence–though is only a fraction of a second–is able to destroy proteolytic
enzymes causing rupture of polysaccharide and lipid membrane peroxidation (LMP) altering
its permeability and associated features [19] (Figure 2). Peroxynitrite (ONOO–) can cause direct
damage to proteins and DNA, and is also a potent inducer of LMP that can destroy neurons,
which are especially sensitive to this process. Oxidative stress can occur in different acute
degenerative conditions such as cerebral ischemia, traumatic brain injury, and chronic
degenerative processes such as Parkinson’s disease [20]; it is observed, to a lesser extent, in
neural circuits during normal physiological activity.
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Figure 2. Damage generated by free radicals (ONOO-, OH-) directly affects proteins, membrane phospholipids, and
DNA molecules. The resulting free radicals, such as superoxide anion (O2-) and hydroxyl radical (OH•), as well as the
nonradical hydrogen peroxide, can damage macromolecules, including DNA, proteins, and oxidized lipids have all
been related in such damages. The superoxide radical, although it is unreactive in comparison with many other radi-
cals, biological systems can convert it into other more reactive species, such as peroxyl (ROO•), alkoxyl (RO•), and
hydroxyl (HO•) radicals.
On the other side, oxidative stress can cause the onset of a disturbance in cellular calcium
homeostasis. This action is usually related to an effect on the receptor mobilizing Ca2+, but the
decrease of Ca2+ ATPase activity is also evident. Reactive oxygen species (ROS) also interfere
with other transduction signal systems through the action of nitric oxide (NO) [21] (Figure 3).
Reactive oxygen metabolites affect ligand binding to membrane receptors such as β-adrener-
gic, cholinergic, muscarinic, histamine, and serotonin. Some reactive oxygen species can affect
enzymatic pathways such as the phospholipase A [22].
Figure 1. Mitochondria are considered the main source of free radicals, which come from the electron transport chain.
Within mitochondria, 2O2+ is produced by the one-electron reduction of O2. Therefore, it is the kinetic and thermody-
namic factors underlying the interaction of potential one-electron donors with O2 that control mitochondrial ROS pro-
duction.
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Figure 3. ROS can disrupt calcium homeostasis through its effect on receptors on the cell gate ionic membrane, calcium
ATPase, and interfere with signal transduction. Interactions between Ca2+ and reactive oxygen species signaling coordi-
nate signaling, which can be either beneficial or detrimental. In neurodegenerative disorders, cellular Ca2+-regulating
systems are compromised. Oxidative stress, perturbed energy metabolism, and alterations of disease-related proteins
result in Ca2+-dependent synaptic dysfunction.
Free radicals formed in the organism can initiate a series of chain reactions which continue,
after several reactions, until removed with other free radicals or by the antioxidant system,
which protects tissues from their deleterious effects. According to the mode of action, three
main types of antioxidants are known: (a) those preventing the formation of new free radicals,
(b) those making them less harmful before they can react, and (c) those preventing the
formation of free radicals from other molecules.
The enzymes involved in the antioxidant system are superoxide dismutase glutathione
peroxidase (GPx), catalase, glutathione reductase, glutathione S transferase, and other proteins
that bind metals (ferritin, transferrin, and ceruloplasmin) limiting the availability of iron
necessary to form the •OH radical.
Excessive ROS reactive nitrogen species (RNS) generation may contribute to cell injury and
death. In particular, accumulation of nitrosative stress due to excessive generation of nitric
oxide (NO) appears to be a potential factor contributing to neuronal cell damage and apoptosis.
In this process, overstimulation of N-methyl-D-aspartate-type of glutamate receptors permit
calcium influx Ca2+ to cell, increasing NO and promoting ROS formation through a process
named S-nitrosylation which consists in a reaction between NO and cysteine thiol to form S-
nitrosothiols (SNOS). In addition, NO can react with superoxide to generate peroxynitrite
(ONOO–), which is highly toxic to cell, as well [23].
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3. Clinical manifestations of Parkinson’s disease
PD is a common neurodegenerative disorder characterized by progressive loss of substantia
nigra dopaminergic neurons, and the concomitant loss of dopaminergic nerve terminals in the
caudo-putamen nuclei, which is the main neuron projection area of the substantia nigra. PD
affects about 1% of the population over 65 years, which increases to up to 4% after the age of
80 [24]. Its main symptoms were described in 1817 by James Parkinson in an essay called the
“shaking palsy.” From a clinical point of view, PD is characterized by tremor at rest, slow
movements (bradykinesia), rigidity, postural instability, stiffness of the muscles, serious
inability to initiate movement (akinesia), and mask-like face expression. Other symptoms may
be a flexed posture, freezing (motor blocks), loss of arm swing on one side, loss of smell, or a
persisting glabellar tap reflex. However, the above mentioned symptoms may not all be present
in one patient [25]. Bradykinesia, slowness of movement, is the most characteristic symptom.
PD patients may therefore show slowness in daily activities and slow reaction times and may
have difficulties in fine motor control [26].
A number of nonmotor features can precede the motor symptoms of PD. These symptoms
probably arise from extra-nigral structures. For instance, olfactory deficits [27] and cardiac
sympathetic denervation [28, 29] are present in a very high proportion of patients presenting
with the earliest motor signs, suggesting that such features probably precede the motor signs
and may be more useful in characterizing early disease status. Other nonmotor symptoms
include autonomic, mood, cognitive, and sensory dysfunctions, as well as sleep disturbances
[30, 31]. Depression is the most frequent psychiatric complication in PD. Although depression
often precedes motor symptoms in PD [32], it may still reflect impairments of the nigrostriatal
dopaminergic circuit [33]. Anxiety is also comorbid with PD [34]. These nonmotor symptoms
significantly contribute to the reduced quality of life in PD patients, but are frequently
undiagnosed and left untreated [35, 36].
4. Physiopathology of Parkinson disease
One of the most surprising aspects of PD is the selective vulnerability of neuronal population
to damage. PD can occur when an external or an internal toxin selectively destroys dopami-
nergic neurons. When the neurons which connect two specific brain regions, the compact part
of the substantia nigra (SNPC) and the striatum, essential to maintain the motor function die,
the dopaminergic pathway progressively degenerates, and the level of dopamine in the
striatum decreases causing changes in brain circuitry and motor features of PD deficiencies
appear.
The main pathological findings of PD are the loss of dopaminergic neurons and formation of
fibril aggregates composed of α-synuclein, called Lewy bodies, in the remaining dopaminergic
neurons located in substantia nigra pars compacta [37]. DA neurons of SNPC also have a
tendency to degenerate with aging at a rate of approximately 5% per decade. In contrast, the
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rate of neurodegeneration in PD patients is about 10-fold faster and occurs mainly in the
ventro-lateral part of SNPC [38].
The degeneration of neuronal cells may be the consequence of many pathogenic factors (toxic,
infectious, genetic, metabolic, vascular, etc.) and the final consequence is apoptosis and cell
death in which caspases (particularly caspase 3) and Bcl-2 protein families are central compo-
nents with up and down regulatory mechanism that promotes apoptosis. Two main caspase-
mediated pathways of cell death have been described in mammals: (a) the extrinsic or death
receptor-mediated pathway, which has a critical role in the maintenance of tissue homeostasis,
and (b) the intrinsic, mitochondria-dependent pathway that is mainly activated in response to
extracellular cues and internal insults such as DNA damage, growth factor deprivation,
cytoskeletal disruption, accumulation of unfolded proteins, hypoxia, and many others [12, 19–
21, 39–42].
In vivo, the dysfunction of the proteasomal system in order to cleave misfolded α-syn due to
lack of energy associated to mitochondrial damage, and problems with the autophagy-
lysosomal degradation pathway, which disrupts damaged mitochondrial clearance, leads to
the formation of protein inclusions and accumulation of damaged mitochondria, a major
source of ROS, which activate the apoptotic cascade as has been mentioned. ROS accumulation
may result in detrimental effects such as lipid peroxidation, protein oxidation, and further
DNA damage. The maintenance of a pool of healthy mitochondria that can meet the bioener-
getic demands of a neuron is therefore of critical importance; this is achieved by maintaining
a careful balance between mitochondrial biogenesis, mitochondrial trafficking, mitochondrial
dynamics, and mitophagy. Removal of damaged mitochondria through mitophagy can lead
to the release of compartmentalized mitochondrial molecules. Once in the cytosol, some of
these molecules, such as cyt-C, Smac/DIABLO, and HtrA2/OMI, are capable of activating
apoptotic routines that lead to cell death. It is then reported that the failure of mitophagy results
in the release of mtDNA into the cell cytosol contributing to mechanisms of cell death [43–47].
The central events in the mitochondrial-dependent cell death pathway are the activation of the
mitochondrial permeability transition pore (mPTP) and the disruption of mitochondrial
membrane potential, which cause the release of apoptogenic molecules and finally lead to cell
death [48]. The protein α-syn is a small acidic protein containing 140 amino acids. This protein
is able to undergo self-aggregation in a nucleation-dependent process to form nonfibrillar
oligomers, protofibrils, and fibrillar aggregates with amyloid-like properties that are poten-
tially cytotoxic to the neurons and it has been shown to be directly degraded in vitro by the 20S
proteasome. Studies of the degradation of aggregated α-syn led us to suspect that oxidation
of Met may play a role in α-syn degradation by the proteasome [46].
It is important to take into account that neuronal loss in PD is also associated to chronic
neuroinflammation through microglial activation by some different mechanism including
overexpression of inducible NOS (iNOS), COX-2, the cytokines tumor necrosis factor-alpha
(TNF-α), and IL-1β and NO or accumulation of heat shock protein 60 (Hsp60) participating in
DA cell death in PD via a mechanism unrelated to cytokine release and could serve as a signal
of CNS injury through activation of microglial cells. Neuromelanin is released from dying
dopaminergic neurons in the SNpc and activates microglia, provoking increase in the sensi-
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tivity of DA neurons to oxidative stress-mediated cell death. Parkinson’s disease-associated
proteins such as α-syn, parkin, LRRK2, and DJ-1 have also been reported to activate microglia,
as well [11, 49].
One of the most surprising aspects of neurodegenerative diseases is the selective vulnerability
of neuronal population to damage. Parkinson’s disease can occur when an external or an
internal toxin selectively destroys dopaminergic neurons. When the neurons which connect
to two brain regions, the compact part of the substantia nigra (SNPC) and the striatum, essential
to maintain the motor function die, the dopaminergic pathway progressively degenerates and
the level of dopamine in the striatum decreases causing changes in brain circuitry, and motor
features of PD deficiencies appear. The high vulnerability of the SNPC neurons to oxidative
agents, compared to neurons in other cerebral regions, may be explained by a combination of
different factors such as reduced antioxidant activity, increased iron concentration, increased
susceptible to DA oxidation, and reduced activity of the mitochondrial complex I (NADH
oxidoreductase) (Figure 4).
Figure 4. SNPC neurons and oxidative agents. External factors, such as neurotoxins, pesticides, insecticides, and en-
dogenous factors such as dopamine (DA), and genetic mutations in PD-associated proteins contribute to oxidative
damage and disruptions in the maintenance of the redox potential leading to destruction of dopaminergic neurons and
cell death. Different pathways contribute to the substantia nigra pars compacta (SNPC) neurons vulnerability to oxida-
tive damage including (a) high susceptibility of DA auto-oxidation, (b) reduced antioxidant activity such as gluta-
thione, and (c) increased iron concentration d) deficits in mitochondrial complex I of the respiratory chain.
Biochemical abnormalities in the brain with PD show deficits in mitochondrial complex I,
decreased extracellular thiols, increased oxidative iron in the substantia nigra, and oxidative
damage, including DNA oxidation, nitration, and increased carbonyl groups of proteins. Lewy
bodies inclusions contain phosphorylated neurofilaments and a protein called α-synuclein
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[50]. Currently, there is evidence of properties of α-synuclein and its possible association with
oxidative stress state present in PD. One such evidence is the notion that one type of amyloid
aggregates of α-synuclein, similar to those observed in vivo, by coincubation with copper (II),
Fe/hydrogen peroxide, or are induced cytochrome c/ hydrogen peroxide. Many motor
characteristics defining the PD result primarily from the loss of substantia nigra neurons [28].
Deficiencies in mitochondrial function, increased oxidative stress, apoptosis, excitotoxicity,
and inflammation, all of them are part of the processes that eventually result in neurodegen-
eration [51].
4.1. Genetic and Parkinson’s disease
A relatively new theory explores the role of genetic factors in the development of Parkinson’s
disease. A total of 15–25% of Parkinson’s patients have a close relative who had experienced
parkinsonian symptoms (such as tremor).
There are many genes linked to familial forms of PD, which have produced advances in PD
basic research, increasing our understanding of possible mechanism of dopaminergic cells
damage in patients with this condition. These genes include those associated with α-syn,
parkin, DJ-1, PINK-1, LRRK-2, ATP13A2, mitochondrial phosphatase, and phosphatase and
tensin homolog (PTEN)-induced kinase gene, and they have been demonstrated to be involved
in apoptosis regulation. Parkin is associated with the outer mitochondrial membrane (OMM)
and prevents cell death by inhibiting mitochondrial swelling, cyt-C release, and caspase
activation. Another finding in pathogenesis has been centered in the ATP13A2 gene, which
regulates intracellular Mn2+ homeostasis, playing an important role in preventing damage
induced by Mn2+ cytotoxicity. Overexposure of cells to Mn2+ may determine cell death by
induction of DNA damage, oxidative stress, disruption of Ca2+, iron homeostasis, and mito-
chondrial dysfunction. In an experimental model, monomeric α-Syn-expressing dopaminergic
cells significantly attenuated Mn-induced neurotoxicity for initial exposures. However,
overexposure to Mn produces precipitation of α-syn, which at the same time impairs antiox-
idative defense mechanism in this experimental model [39, 44, 52].
One important finding of PD is the presence of cytoplasmic inclusions containing α-synuclein
and ubiquitin, known as Lewy bodies, in the SNPC and other brain regions. Some cases of
familial PD are clearly attributed to mutations in the genes for α-synuclein and parkin.
4.2. Dopamine as a source of ROS in the CNS
Since the discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine infusion causes
parkinsonism by selective inhibition of mitochondrial complex-1, raised the possibility that
mitochondrial dysfunction is at the heart of PD [53].
In patients with PD, there is an excess amount of cytosolic DA outside of the synaptic vesicles
due to damaged neurons with impaired reuptake, and a possible increased damage when an
overload is related to levodopa treatment. Dopamine is easily metabolized via monoamine
oxidase (MAO). Also DA suffers auto-oxidation to cytotoxic ROS producing mitochondrial
impairment either by activation of the intrinsic apoptotic pathway or by inhibiting the
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respiratory chain. Also, the auto-oxidation of DA produces electron-deficient DA quinones or
DA semiquinones, which, at the same time, modify some PD-related proteins, such as α-syn,
parkin, DJ-1, superoxide dismutase-2 (SOD2), and UCH-L1. Additionally, DA quinones can
be oxidized to aminochrome, whose redox-cycling leads to the generation of the superoxide
radical and the depletion of cellular nicotinamide adenine dinucleotide phosphate-oxidase
(NADPH), which ultimately forms the neuromelanin, contributing to this degenerative
mechanism [11, 47] (Figure 5).
Figure 5. Dopamine as a source of ROS in the CNS. In patients with PD there is an excess amount of cytosolic dopa-
mine (DA), this molecule is unstable and undergoes auto-oxidation to form dopamine quinones and free radicals that
leads to modification of PD-related proteins such as α-syn and mitochondrial impairment. The products of dopamine
oxidation, dopamine quinones, can also contribute to neurodegeneration. Dopamine quinones can cyclize to form dop-
aminocromo who is the precursor of neuromelanin, a brain pigment that may contribute to neurodegeneration.
The microtubule (MT) system may play an important role in PD pathogenesis, as well. It is
crucial for many aspects of neuronal function, including motility, differentiation, and protein
and organelle trafficking. In experimental models, both acute and chronic sub-lethal settings,
6OHDA-induced oxidative stress elicited significant alterations in microtubule (MT) dynam-
ics; very important for axonal transportation; these includes reductions in MT growth rate,
increased frequency of MT pauses/retractions, and increased levels of tubulin acetylation [54].
DA metabolism act as proneurotoxins in the development of PD. Certain components of snuff
smoke can react with these proneurotoxins preventing its activation. This may explain the
possible beneficial effect of smoking on the incidence of PD. The ROS generated by the auto-
oxidation of dopamine have been implicated in the neuron loss; related to age and other
neurodegenerative disorders such as PD. To date, there have been proposed two mechanisms
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by which the DA stimulates the production of ROS. These depend on the presence or absence
of enzymatic mediators [55]. The DA in the substantia nigra and striatum is spread by the
enzyme monoamine oxidase (MAO), located in the outer membrane of mitochondria [56], from
this reaction results the superoxide and hydroxyl radicals plus hydrogen-peroxide production.
Another derivative compound is 1,2,3,4 tetrahydropapaverolin DA (THP) obtained from
enzymatic catabolism. TTP itself is capable of inducing necrosis in neuroblastoma cells and is
related to the pathogenesis of PD [57].
DA is a molecule with a catechol group which cannot be easily enzymatically oxidized to form
an array of electrochemical species (quinone type). First, the initial step in the oxidation of DA
involves a reaction with molecular oxygen to form DA quinone and two molecules of super-
oxide anion. Second, the superoxide anions formation during autoxidation of DA leads to the
production of hydrogen peroxide by the dismutation of superoxide. Third, in this way, iron
mediated in substantia nigra showed high amounts of oxidative stress. Last, the total iron
increased but does not necessarily mean an oxidative stress state as excess iron always store
into the proteins, such as ferritin, which leaves the iron inert and harmless [58].
However, that state of iron stability can change by continuing entry and release of iron from
ferritin to more active form entering the Fenton reaction generating the hydroxyl radical. The
iron accumulates in astrocytes in the substantia nigra (experimental data), increasing the rate
of Fe(III)/Fe(II) and reduced glutathione. Aging may be a factor which predisposes the brain
to the PD, due to, according to our interpretation, the kidnapping by the mitochondria of Fe(II)
in astroglia in the substantia nigra. Furthermore, there is evidence that the intracellular loss of
redox balance results in aberrant dopamine oxidation in 6-hydroxydopamine, which in turn
can undergo auto-oxidation to quinones and simultaneously generate superoxide. This
cascade reaction, either by itself, or amplified by the generation of ROS, may explain the
neuronal loss as an end result. The DA-o-quinone then undergoes intramolecular cyclization
to form 5,6-dihydroxyquinoline, which is subsequently oxidized by the DA-o-quinone to form
dopaminocromo; this compound undergoes a rearrangement to form 5,6-dihydroxyindole,
which in turn is oxidized into a quinone indole. The following polymerization process finally
leads to the generation of a dark pigment called neuromelanin. The dark appearance of the
black substance is due to the presence of this pigment containing oxidation products of the
cysteinyl-DA.
Dopaminergic neurons are particularly exposed to oxidative stress due to the metabolism of
dopamine that causes a series of molecules that are potentially toxic if they are not adequately
removed. Dopamine acts as a free radical generating compound, and can oxidize itself at
physiological pH, generating dopamine-forming toxic quinones, superoxide radicals, and
hydrogen peroxide [40]. It can also be enzymatically deaminated by monoamino oxidase
(MAO) to 3,4-dihydroxyphenylacetic, a nontoxic metabolite acid (DOPAC), hydrogen perox-
ide [41], and by other oxidative processes. Thus, the metabolism of dopamine generates high
concentrations of ROS, which can activate and induce apoptotic cell death cascades [19, 20].
ROS accumulation is toxic per se, and generates oxidative stress as a result of depletion of
cellular antioxidants (e.g., vitamin E and reduced glutathione), increase the membrane lipid
peroxidation, DNA damage, and oxidation alteration of protein folding [20]. Besides the
Oxidative Stress and Parkinson’s Disease: Effects on Environmental Toxicology
http://dx.doi.org/10.5772/63794
193
general oxidative damage, there is evidence that the interaction between α-synuclein and
dopamine metabolites determines the preferential neurodegeneration of dopaminergic
neurons. Along with a number of possible changes, abnormal protein aggregates could also
act as irritants, causing a chronic inflammatory reaction which can induce synaptic changes
and neuronal death. Findings which suggest the existence of a chronic inflammation process
include the presence of microglial activation and astrocytosis in the brain of these patients,
particularly in the vicinity of protein aggregates. In PD, along with several toxic and genetic
mechanisms producing neuronal damage, the compounds released from damaged neurons
can induce microglial release of neurotoxic factors aggravating neurodegeneration [36].
Among those released is neuromelanin compound which is a strong iron chelator. The
neuromelanin-ferrum complex activates microglia in vitro, causing the release of neurotoxic
compounds such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and nitric oxide
(NO). Increased total iron concentration had been described in the substantia nigra of PD
severe cases, although the underlying mechanism is not known [59]. Iron also contributes to
increasing the generation of oxygen radicals (ROS), oxidative stress, and increased protein
aggregation, including α-synuclein aggregation. The rapid aggregation of α-synuclein protein
in turn can induce the formation of ROS. Lastly, dopamine stabilizes the protofibril form of
α-synuclein, which would be toxic. Thus, in the oxidative atmosphere of a dopaminergic
neuron, α-synuclein is involved in generating a vicious circle, which leads to neuronal death
[59] (Figure 6).
Figure 6. Interaction between α-synuclein and dopamine metabolites. Dopamine metabolites such as neuromelanin-
Ferrum complex produce microglial activation that leads to chronic inflammation process, causing the release of inter-
leukins, and free radicals. The reactive oxygen radicals interact with total iron concentration in the substantia nigra
and increase the propensity of the α-synuclein to aggregate. This protein is present in Lewy bodies and the formation
of aggregates is associated with increased oxidative stress, neurodegeneration, and cell death.
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Finally, till date there have been at least five different mechanisms of death in neurons with
dopaminergic dysfunction associated to oxidation of the dopamine (DA): (1) proteasome
dysfunction, (2) mitochondrial dysfunction, (3) oxidative stress, (4) α-syn oligomers precipi-
tation, and (5) lysosomal autophagy dysfunction.
Another possible mechanism implicated in neuronal destruction and death is associated with
diminished neuroprotection due to the dysfunction of neuromelanin and diaphorase enzyme
[45, 56].
4.3. MPTP and Parkinson’s disease
In 1982 (California, USA), a group of recreational drugs were developed which severely causes
parkinsonian syndrome days after injection; 1-methyl-4-phenyl-4-propionoxipiperidina
(MPPP), a synthetic analog of meperidine, was used for that purpose. This analog-product,
according to the analysis of samples provided by the seller, was contaminated by 1-methyl-4-
phenyl-1,2,3,6 tetrahydropyridine, which was discovered to cause parkinsonism at a concen-
tration of 2.5–2.9% by weight. Initial clinical symptoms shown by these patients were treated
with carbidopa/L-dopa. In the following years, the clinical treatment was insufficient to halt
the progression of the disease and died 12 and 16 years, respectively, after injection. Patholog-
ical analysis of their brains showed moderate to severe decrease of neurons in the substantia
nigra without Lewy bodies. Besides, gliosis and clumping of microglia around nerve cells were
found [60].
In 1991, an individual, 39 years old, tried to produce the MPPP following the instructions of a
chemistry textbook and obtained, without knowing, the by-product MPTP. Approximately, 45
g of the drug in the course of a week were injected. At the end of this period, he had language
problems, remained lethargic, and developed rigid posture. These symptoms worsened over
the next week, so he had to be admitted to a hospital. In the next two weeks, he was treated
with selegiline and carbidopa/L-dopa, which greatly improved their symptoms. Over the next
3.5 years, the patient responded transiently to treatment with carbidopa less/L-dopa and
bromocriptine; however, his condition progressed to severe parkinsonism immobility and a
significant hypophonia and died. Neuropathological analysis of this patient showed similar
findings to those found in the brains of those patients studied from California. Besides, large
amounts of extraneuronal melanin were found indicating a progressive death of nerve cells in
response to a brief temporary aggression the nigrostriatal system. The above data show that
the acute phase of parkinsonian syndrome is completed within a few days after administration
of MPTP; however, neurodegeneration caused by MPTP silently continue for several years or
even decades [61, 62].
From a neurochemical point of view there is a great similarity between the MPTP-induced
parkinsonism and PD. The neurotoxic action of MPTP involving dopaminergic transmission
produces a variety of neurochemical changes: (1) decrease in the concentration of dopamine
and its metabolites (3,4-dihydroxyphenylacetic acid and homovanillic acid), (2) decrease
activity of the enzyme tyrosine hydroxylase, and (3) alteration in the density of dopamine
receptors.
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Since the discovery of the effect of MPTP in human, extensive research in animal models, cell
cultures, etc. was initiated to characterize in more detail the effects of the toxin.
MPTP produces selective death of dopaminergic neurons and parkinsonian syndrome in
several species, including Rhesus monkeys, squirrel monkeys, and beagle dogs. The effects of
MPTP, presented in a variety of nonhuman primates, consist in a very significant reduction in
spontaneous activity, rigidity, tremor, and bradykinesia. Very few human subjects develop
resting tremor characteristic of PD. MPTP initially produces temporary parkinsonian symp-
toms but become permanent with repeated administration of the toxin. The mechanisms
involved in spontaneous recovery experienced by these animals are not known, but may be
related to a transient alteration of other neurotransmitter systems other than nigrostriatal. On
the other hand, rats and guinea pigs do not show permanent impairments of DA in the striatum
nor they present movement disorders such as those observed in primates. In mice of the C57BL/
6 strain MPTP induces toxic changes, but at higher concentrations.
There is no evidence that MPTP induces alterations in the cholinergic, GABAergic, and
glutamatergic systems in primates. However, the levels of various neuropeptides, substance
P, dynorphin, and enkephalin in striatum, substantia nigra, and globus pallidus are reduced
in animals chronically treated with MPTP. These same abnormalities have been described in
patients with PD. However, it is not known whether they are due to the degeneration of
neurons containing these peptides or represent adaptive nigrostriatal denervation to changes.
The susceptibility of different animal species to MPTP may be related to differences in the
metabolism of MPTP, cerebral distribution, and retention of the final metabolite [63].
4.4. Metabolism of MPTP
MPTP metabolism is a complex process, after systemic administration it readily crosses the
blood brain barrier due to their lipophilicity. Once in the brain, it is transformed extraneuro-
nally in astrocytes, a monoamine oxidase B rich cells, into the intermediate, 1-methyl-4-
phenyl-2,3-dihydropyridinium (MPDP+). This is a very reactive ion undergoing autoxidation
to the radical 1-methyl-4-phenyl pyridinium (MPP+) with the formation of superoxide anion
(O2•). Besides, the MPDP+ readily crosses the cell membrane and into the extracellular space
to form MPP+ and O2•. Extracellular MPP+ is leaking from astrocytes and used by the
presynaptic DA system uptake, resulting in an energy-dependent concentration in dopami-
nergic neurons [64].
Intraneuronal concentration of MPP+ increases by binding to neuromelanin and then brought
into the mitochondrial matrix through active transport system, which acts as a potent inhibitor
of complex I of oxidative phosphorylation system. This effect is due MPP+ binding to complex
I at a distal sulfur iron site core and near the binding site of ubiquinone Q10. This leads to the
cessation of oxidative phosphorylation, ATP level is depleted and decreases the concentration
of the major cellular antioxidant, reduced glutathione. This also leads to changes in cellular
calcium, altered transmembrane potential, and ultimately neuronal death is manifested [65].
The inhibition of mitochondrial complex I can increase oxidative stress induced by MPP+, since
the electrons inside the mitochondria may contribute to the toxic effects of MPTP. For example,
Free Radicals and Diseases196
it has been demonstrated that MPP+ induced lipid peroxidation in cultured cells and the DA
is blocked by specific inhibitors of lipid peroxidation [66] (see Figure 2).
4.5. Toxicology of paraquat
The LD50 of paraquat in humans is about 3–5 mg/kg, which represents only 10–15 ml in a 20%
solution. Although paraquat is regarded as moderately hazardous substance and the Envi-
ronmental Protection Agency classifies it as a possible human carcinogen and weakly geno-
toxic, the toxic potential of this herbicide is very high [67].
The genotoxic potential of paraquat has been studied in our research group through induced
micronuclei in erythrocytes and bone marrow of mice. Paraquat (15 or 20 mg/kg) was injected
intraperitoneally at an interval of 24 hours and then every 6 hours until completion of the study
(72 hours). We found that treatment with paraquat increases the number of polychromatic
erythrocytes micronucleus cells in blood and bone marrow. Also in this work, it was found
that the administration of melatonin, an efficient free radical scavenger, at doses of 2 or 10 mg/
kg, 30 min before injection of paraquat partially reverses micronucleus formation [68].
The widespread use of paraquat carries great risk potential for misuse and also for accidental
and intentional poisonings. Therefore, the label for minimum safety should be increased
because recommendations for it use is not strictly followed. Particularly to protect the skin,
equipment is required for face and hands. Poisoning usually occurs in the first instance through
the skin when in direct contact with the backpack spray of the herbicide. The eyes and nose
may also be exposed to the herbicide. Toxic effects include mild irritation, blistering, peeling,
necrosis, dermatitis, and dermatitis of hands and sometimes of the scrotum. Severe exposure
to the hands causes localized discoloration or temporary loss of nails. Splashes in the eyes can
cause irritation and inflammation of eyelids and decreased visual acuity. Although the intact
human skin is relatively impermeable to paraquat, some fatalities as a result of dermal
exposure are documented. The presence of scratches, cuts, wounds, or severe dermatitis can
substantially increase the risks [69].
The lungs are the first target of paraquat, and pulmonary effects represent the most lethal and
least treatable manifestation. The inhalation toxicity is rare. The main mechanism of cell
damage is the generation of free radicals that oxidize lung tissue. Although acute pulmonary
edema and lung damage after several hours of severe acute exposures may occur, delayed
pulmonary fibrosis is the usual cause of death that commonly occurs 7–14 days after ingestion.
In some patients, ingestion of a large amount of concentrated paraquat form (20%) died more
rapidly due to circulatory failure (within 48 hours). Lung cells appear to selectively accumulate
paraquat which generates free radicals causing lipid peroxidation and cell damage. Hemor-
rhage, fluids, and leukocytes infiltrates into the alveolar spaces, followed by fibroblast
proliferation. There is a progressive decrease in arterial oxygen tension and diffusion capaci-
ty of CO2. Such deterioration in gas exchange causes progressive proliferation of fibrous
connective tissue in the alveoli eventually causing death by asphyxiation and tissue anoxia [70].
In the gastrointestinal tract, toxicity first occurs at the mucosal layers after paraquat ingestion.
This causes swelling, edema, and painful ulceration of the mouth, pharynx, esophagus,
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stomach, and intestine. At high doses of paraquat, hepatocellular damage occurs, which is
manifested by increased serum liver enzymes. Also, the deterioration of renal function may
play an important role in determining the outcome of paraquat poisoning. Normal tubular
cells secrete paraquat in urine quickly, efficiently removing it from the blood. However, high
blood concentrations of poison affect the secretory mechanism and may destroy the cells.
Ingestion or accidental or deliberate exposure to paraquat has been responsible for many
deaths. In one study, done in 1989 in Sri Lanka, found that out of 669 cases of poisoning,
agrochemicals were responsible for 59% of toxicity and paraquat was the most common agent
with a fatality rate of 68%. Even in the United Kingdom, in the years 1990–1991 there were 44
deaths with paraquat.
In Sweden, Denmark, Finland, and Austria, the use of paraquat is prohibited. In 2003, Syngenta
pursued the Standing Committee on the Food Chain and Animal Health of the European
Commission to include the authorization policy of EU pesticides. Subsequently, in August
2005, Austria, Finland, and Denmark opposed the use of paraquat. This is because it has
sufficient evidence linking chronic use of paraquat with Parkinson’s disease (PD) as described
below. Moreover, paraquat residues in food are usually not detectable, except when this
herbicide is used before getting the harvest of crops such as cereals, pineapple, etc. These foods
have been reported to have levels of up to 0.2 mg/kg, whereas the acceptable daily intake is
0.004 mg/kg.
In the case of smoking marijuana contaminated with paraquat, the toxic effects are rare or
nonexistent. Most paraquat that contaminates marijuana is pyrolyzed during the combustion
of cigarette becoming bipyridyl, which is known to be very less toxic [71].
4.6. Toxicology of diquat
In humans, diquat is not systemically selectively absorbed nor concentrated in the lung tissue,
as paraquat do, therefore, lung injury caused by diquat is less. However, diquat has severe
toxic effects on the central nervous system that are not typical of paraquat poisoning. In many
cases of human diquat poisoning, the medical signs and symptoms of neurological toxicity are
the most important. These include nervousness, irritability, restlessness, combativeness,
disorientation, nonsensical statements, diminished reflexes, and inability to recognize friends
or family members. Neurologic effects may progress to coma, accompanied by tonic-clonic
convulsions resulting in death. Also, parkinsonism was reported after skin exposure to diquat.
Another interesting aspect is the recognition of the role of inflammation and oxidative stress
in the pathogenesis of PD. For example, in postmortem studies of some patients who were
exposed to MPTP activation of microglia around neurons was found. So in our laboratory, we
investigated the effect of MPTP over the activity of cyclooxygenase 2 (COX-2) using mice from
the C57/BL6 strain. Our data indicate that a single dose of MPTP in mice had the following
effects: a significant increase in the peroxidase activity of COX-2 in midbrain, compared with
controls and increased nitrite levels and lipoperoxides in serum. These effects were presented
after 24 hours of treatment. We also found that melatonin partially reverses the effects of MPTP
on the activity of COX-2 and levels of nitrites and lipoperoxides in serum. The oxidative stress
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induced by MPTP in the mouse midbrain is also reflected in the serum, suggesting a systemic
MPTP damage, which is reversed by melatonin, due to its antioxidant action. The action of
melatonin can be attributed to the decrease of oxidizing species like dopamine-quinone. It has
been further suggested that the cytotoxicity of neuronal COX-2 can come from the formation
of reactive oxygen species generated during the catalysis of peroxidase activity of the enzyme
[72].
4.7. Herbicides and Parkinson’s disease
Structural similarity of the MPP+ and paraquat suggested that this herbicide could be toxic to
dopaminergic neurons. In 1985, it was found that paraquat produced a parkinsonian behavior
in leopard frogs (Rana pipiens). Whereas in mice of strain C57BL/6 systemic administration of
paraquat resulted in a loss of dopaminergic neurons, degeneration of striatal dopaminergic
fibers, and a reduction in ambulatory activity. Subsequently, in humans, the incidence of PD
positively correlates with exposure to pesticides, including paraquat, in patients from some
regions of Canada, Taiwan, and elsewhere.
Paraquat neurotoxicity is associated with their ability to induce the formation of free radicals,
to induce the fibrillation α-synuclein, and to induce cell death by apoptosis [72].
4.8. Other pesticides and Parkinson’s disease
Another class of chemicals associated with PD in humans is certainly having dithiocarbamates,
such as maneb. In vitro studies show that neurotoxicity induced by maneb is related to the
enzymatic inhibition of mitochondrial complex III and the oxidation of catecholamines.
Systemic administration of paraquat and maneb induce a synergistic decrease in the content
of DA in the striatum, SNPC degeneration, and motor abnormalities. Moreover, neonatal
exposure of both pesticides increases the susceptibility of nigrostriatal dopaminergic system
in maturity [73, 74].
Several plants (Derris elliptica, Lonchocarpus, and Tephrosia) contain the insecticide rotenone,
which is a specific inhibitor of mitochondrial complex I. Its exposure to humans has been
associated with PD. In rats, continuous systemic administration of rotenone reproduces the
key aspects of PD including the selective degeneration of the nigrostriatal dopaminergic
system, like the formation of cytoplasmic inclusions, Lewy bodies, and movement disorders.
The effect of rotenone is mediated by the enzyme activity of microglial NADPH oxidase, which
is the main source of O2• radical [75, 76].
Also, organochlorine insecticides such as dieldrin are associated with motor disorders
observed in ducks, pigeons, and rats. Furthermore, dieldrin residues detected in brains of PD
patients, in cultured cells in vitro, shows selective dopaminergic neurotoxicity, which is
mediated by the formation of oxygen-free radicals, lipid peroxidation, and fibril formation,
α-synuclein. Also, some organophosphorus insecticides are associated with PD in humans.
It remains to be determined whether exposure to pesticides explains some cases of PD. A
valuable tool to help determine this has been studies in which high doses of the pesticide are
used for short periods and chronic application of these toxic in animal models [77].
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4.9. Medical treatment of Parkinson’s disease
Medical treatment of PD is usually based on anticholinergics, amantadine, levodopa, and other
dopaminergic drugs. These agents maintain a good quality of life for most patients; however,
when the disease progresses, it usually becomes ineffective and can cause adverse effects. So
far, the most potent treatment of PD is L-dopa. However, L-dopa motor complications of
chronic administration have emerged as a major limitation in response to treatment. That is
why, in the future, neuroprotective therapies would slow the progression of the disease and
delay the L-dopa need. There is insufficient evidence that L-dopa therapy prevents the
progressive death of nigrostriatal neurons, but instead there is speculation that it may
contribute to the progressive disease course. In the past years, they have contributed new
knowledge about the mechanisms of neurodegeneration present in the PD [78].
4.10. Mitochondria and Parkinson’s disease
Mitochondria participate in numerous cellular functions including ion homeostasis, heme and
steroid synthesis, calcium signaling, and apoptosis [79, 80]. The well-known role of this
organelle is to generate energy for cellular metabolism by the oxidative phosphorylation
system. Electrons derived from cellular metabolism reach the mitochondria through two key
coenzymes. Then they undergo a passage throughout the electron transport chain that consists
of five protein complexes located in the inner mitochondrial membrane. Electrons pass through
complexes I, III, and IV thanks to a proton gradient generated by the transport of these
complexes to the outer side of the inner mitochondrial. In this process, the electron leakage
from the respiratory chain induces the conversion of oxygen (0.4–4%) in superoxide radicals.
As a consequence mitochondria are the primary source of ROS [81].
In the mitochondrial respiratory chain, the complexes I and III are the major sites of superoxide
production. Partially reduced forms of oxygen are highly active; they chemically interact with
biological molecules, resulting in oxidation of protein, DNA and RNA, and peroxidation of
lipids. The damaging effects of ROS are counteracted by endogenous antioxidant enzymes
such as catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase,
and by molecules such as glutathione, metallothionein, and vitamins A, C, and E. Then cell
death may be as well associated with decreasing capability to clear ROS by mitochondria [82–
84].
Complex I of the respiratory enzyme is decreased in substantia nigra in patients with PD,
possibly causing electron leakage from the electron transport system and increasing in the
generation of peroxide anion (O2–). This produces increasing activity in the manganese-
superoxide dismutase (Mn-SOD), which is demonstrated in autopsied parkinsonian brains.
Therefore, it indicates an increase in the generation of O2– in the mitochondria, resulting in an
increase in the generation of hydrogen peroxide. Levels of cytokines, such as TNF- or,
interleukin-1/3, and interleukin-6, are elevated in the striatum, indicating activation of
astrocytes and/or microglial cells. The activation in the microglial cells increases the nitric oxide
(NO–) formation through the diaphorase system, and diffused to nerve terminals and dopa-
minergic cells in the central nervous system. NO– reacts with O2– to produce peroxynitrate.
On the other hand, iron is accumulated in astrocytes and microglia and NO– provokes ferric
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ion conjugation with ferritin, which is slowly released from cells to the intercellular space.
Other proposed mechanism of oxidation is union of iron to oxygen and L-DOPA to iron (or
copper) in the complex 27 of the mitochondrial chain, possibly initiating a lipid peroxidation
in the cell membrane [85].
The genes linked to familial forms of PD include those associated with α-syn, parkin, DJ-1,
PINK-1, LRRK-2, ATP13A2, mitochondrial phosphatase, and phosphatase and tensin homolog
(PTEN)-induced kinase gene, between others, and they have been demonstrated to be involved
in apoptosis regulation. Parkin is associated with the outer mitochondrial membrane and
prevents cell death by inhibiting mitochondrial swelling, cyt-C release, and caspase activation.
Another finding in pathogenesis has been centered in the ATP13A2 gene, which regulates
intracellular Mn2+ homeostasis, playing an important role in preventing damage induced by
Mn2+ cytotoxicity. Overexposure of cells to Mn2+ may determine cell death by induction of DNA
damage, oxidative stress, disruption of Ca2+ and iron homeostasis, and mitochondrial dys-
function. In an experimental model, monomeric α-Syn-expressing dopaminergic cells
significantly attenuated Mn-induced neurotoxicity for initial exposures. However, overexpo-
sure to Mn produces precipitation of α-syn, which at the same time impairs antioxidative
defense mechanism in this experimental model [86–88].
Other findings suggested that mitochondrial dysfunction is at the heart of PD. For instance,
MPTP infusion causes parkinsonism by selective inhibition of mitochondrial complex-1 [89].
In patients with PD there is an excess amount of cytosolic dopamine outside of the synaptic
vesicles due to damaged neurons with impaired reuptake, with a possible increased damage
when an overload is related to levodopa treatment. Dopamine then is easily metabolized via
monoamine oxidase or by auto-oxidation to cytotoxic ROS provoking mitochondrial impair-
ment by activating the intrinsic apoptotic pathway or by inhibiting the respiratory chain. Also,
the auto-oxidation of DA produces electron-deficient DA quinones or DA semiquinones,
which at the same time can modify some PD-related proteins, such as α-syn, parkin, DJ-1,
superoxide dismutase-2, and UCH-L1. Additionally, DA quinones can be oxidized to amino-
chrome, whose redox-cycling leads to the generation of the superoxide radical and the
depletion of cellular nicotinamide adenine dinucleotide phosphate-oxidase (NADPH), which
ultimately forms the neuromelanin, contributing to this degenerative mechanism [11].
5. Conclusion
There are many proposed mechanisms that may produce damage to dopaminergic neurons,
but all of them finally converge in a common pathway involving ROS/RNS and mitochondrial
dysfunction that promotes apoptosis. Exposure to environmental factors or mutations in PD-
associated genes of patients with either sporadic or familial PD may cause mitochondrial
dysfunction that ultimately results in PD. In the near future, neuroprotection may coincide
with reductions in intracellular reactive oxygen species, lipid peroxidation, and DNA damage
in the effort to save neurons from death avoiding neurodegeneration to advance until the point
of neither manifesting PD symptoms nor producing advanced symptoms in a patient with
evident motor PD.
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